Lewes, DE -- (SBWIRE) -- 10/02/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Tellabs, Inc. (NASDAQ:TLAB), Integrated Device Technology Inc (NASDAQ:IDTI), Sangamo Biosciences, Inc. (NASDAQ:SGMO), Avanir Pharmaceuticals Inc (NASDAQ:AVNR).
Tellabs, Inc. (NASDAQ:TLAB), increased3.48% and closed at $2.35 on a traded volume of 2.23 million shares, in comparison to 2.07 million shares of average trading volume. So far this year, the stock is up over 3.07%.
The company has a total market capitalization of $835.79 million and its total outstanding shares are 355.66 million.
Will TLAB Continue To Move Higher? Find Out Here
Tellabs, Inc. is engaged in designing and marketing equipment and services to communications-services providers worldwide.
Integrated Device Technology Inc (NASDAQ:IDTI), plunged -0.11% and closed at $9.41 on a traded volume of 2.19 million shares, whereas its average trading volume is 1.60 million shares. In the last three months, the stock is up16.17%. The Intra-day range for the stock is $9.33 and $9.52.
Has IDTI Found The Bottom and Ready To Move Up? Find Out Here
Integrated Device Technology, Inc. (IDT) designs, develops, manufactures and markets a range of semiconductor solutions for the advanced communications, computing and consumer industries.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), jumped up14.39% and closed at $12.00. So far in three months, the stock is up 50.56%. The 52-week range for the stock is $4.92 and $12.01 and during the previous trading session it marked$12.01 as its highest price. The stock initially exchanged hands with a price of $10.45 and the overall traded volume that day was 2.12 million shares.
Will SGMO Continue To Move Higher? Find Out Here
Sangamo BioSciences, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (DNA)-binding proteins (ZFPs), a naturally occurring class of proteins.
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) after opening its shares at the price of $4.22, jumped up3.55% to close the day at $4.38. The stock ended on a traded volume of 2.10 million shares, in comparison to 4.05 million shares of average trading volume. The 52-week range for the stock is $2.07 and $4.05 and during the previous trading session the stock scored the highest price of $4.44. It started the day at $4.22.
Why Should Investors Buy AVNR After The Recent Gain? Just Go Here and Find Out.
AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system.
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/